Piper Sandler Initiates Coverage On Benitec Biopharma with Overweight Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Benitec Biopharma (NASDAQ:BNTC) with an Overweight rating and a price target of $30.
June 13, 2024 | 9:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Benitec Biopharma with an Overweight rating and a price target of $30, indicating a positive outlook for the stock.
The initiation of coverage with an Overweight rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100